Navigation Links
David W. Keiser to Retire as President of Alexion

Co-Founder Remains On Board Of Directors

CHESHIRE, Conn., Nov. 11 /PRNewswire-FirstCall/ -- Alexion Pharmaceuticals, Inc. ("Alexion," the "Company," Nasdaq: ALXN) announced today that David W. Keiser, the Company's Chief Operating Officer since 1992 and President since 2002, will retire by the end of 2008. Mr. Keiser, a co-founder of Alexion, played a central role in the commercial launch of Soliris(R) (eculizumab) in the United States and Europe, and helped to build a broad platform for continued growth in those and other territories. He will remain on Alexion's Board of Directors at least through the expiration of his current term in 2009 and will be available to consult with management and the Board in the future. Mr. Keiser's responsibilities will be distributed among current members of Alexion's senior management reporting to Leonard Bell, M.D., Chief Executive Officer of Alexion.

Mr. Keiser joined Alexion as Executive Vice President and Chief Operating Officer shortly after the Company was established in 1992, bringing to the start-up organization nearly 15 years of international experience with leading pharmaceutical companies including Hoffmann La Roche and G.D. Searle. At Alexion, he played a central role in managing the Company's manufacturing and regulatory efforts, and then initiated the establishment of the Company's commercial teams in the U.S. and Europe to support the 2007 launch of Soliris, the Company's first commercial product, a life-changing biopharmaceutical therapy for patients with paroxysmal nocturnal hemoglobinuria, a rare, debilitating and life-threatening disease.

"David is a unique individual and executive and I have enjoyed working with him as Alexion built its global organization. His top-level expertise and broad experience were instrumental in our evolution from the early group of scientists into an international organization that is now able to deliver Soliris to a growing number of patients in a growing number of countries," said Leonard Bell, M.D., Chief Executive Officer of Alexion and principal founder of the Company. "Under David's leadership, we initiated the development of our world-class teams in the U.S. and Europe, and laid a strong foundation for market entry in Asia and the Pacific, the Middle East and Latin America. We are deeply grateful to his numerous, durable contributions to Alexion, and to the people and processes he has put in place to ensure our ongoing success in coming years."

"I feel privileged to have been a part of what we have accomplished here at Alexion," said Mr. Keiser. "Our scientists are among the very few in the industry to have produced a major, life-changing biopharmaceutical product, and I am pleased to have had a role in bringing the benefits of Soliris to large numbers of patients worldwide. As I leave the day-to-day operations of the Company, I am gratified by the breadth and depth of Alexion executives who are in place and continue to passionately drive to fulfill our global commitments to patients."

In addition to his work at Alexion, Mr. Keiser has been active in various industry organizations and community activities and he will pursue these and other personal interests in retirement.

About Alexion

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company working to develop and deliver life-changing drug therapies for patients with serious and life-threatening medical conditions. The Company is engaged in the discovery, development and commercialization of therapeutic products aimed at treating patients with a wide array of severe disease states, including hematologic diseases, cancer and autoimmune disorders. In March 2007, the FDA granted marketing approval for the Company's first product, Soliris for all patients with PNH. In June 2007, the European Commission granted marketing approval for Soliris in the European Union for all patients with PNH. The Company is evaluating other potential indications for Soliris, as well as other formulations of eculizumab for additional clinical indications. In addition, Alexion is pursuing development of an anti-CD200 monoclonal antibody as a treatment for patients with cancer, and evaluating development of other antibody product candidates in early stages of development. This press release and further information about Alexion Pharmaceuticals, Inc. can be found at:


SOURCE Alexion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. St. Davids HealthCare Launches The TIA Center for Stroke Prevention at St. Davids Medical Center
2. Ortiz to Host Celebrity Golf Tournament to Benefit The David Ortiz Childrens Fund
3. Aflac Celebrates With Petersons Harley Davidson of Miami as 100,000th Online Billing Customer
4. Sunrise Senior Living Appoints Glyn Aeppel and David Fuente to its Board
5. Texas Cardiac Arrhythmia Institute at St. Davids Medical Center First in the Nation to Use a New Generation of Medical Robots for Complex Electrophysiology Mapping Procedures
6. Anpath Group, Inc. Announces Appointments of David V. Gilroy and Paul A. Boyer to Board of Directors
7. David B. Samadi, MD, Demonstrates Robotic Prostate Surgery During Live Webcast, August 13, 2008
8. Los Angeles Jewish Home Selects Community Volunteer David Swartz as its Board of Directors Chair
9. American Biosurgical Adds David Brazeal, CPA as Chief Financial Officer
10. Portable Endoscopic Company Announces Hiring of David Guy as COO/President
11. SFMS David Perlman Award For Excellence in Medical/Health Reporting Recognizes Local Reporters
Post Your Comments:
(Date:11/26/2015)... ... November 26, 2015 , ... ... eReferral system for diagnostic imaging in the Waterloo region. Using the Ocean Platform, ... Medicine tests directly from their electronic medical record (EMR) without the need for ...
(Date:11/26/2015)... (PRWEB) , ... November 26, 2015 , ... ... of workshops to discuss bioavailability and the need to integrate dose form selection ... in collaboration with OBN, the membership organization supporting and bringing together the UK’s ...
(Date:11/26/2015)... (PRWEB) , ... November 26, 2015 , ... PRMA Plastic ... November 19, 2015, our surgeons performed their 6,000th free flap breast reconstruction surgery! , ... wake up every day excited to rebuild lives and it’s an honor to have ...
(Date:11/26/2015)... ... November 26, 2015 , ... Pixel Film Studios brings Final ... ProTrailer: Vintage. This newly styled ProTrailer pack comes with 30 all-new vintage-inspired designs, ... giving users limitless opportunities to stylize and create designs quickly and easily, all ...
(Date:11/26/2015)... ... November 26, 2015 , ... Indosoft Inc., developer and distributor of the ... to improve system efficiency and reliability. , The new Q-Suite 6 platform is based ... system avoids locking itself into a specific piece of software for many key components ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... , November 26, 2015 ... the addition of the  "2016 Future ... European Therapeutic Drug Monitoring (TDM) Market: ... Intelligence, Emerging Opportunities"  report to their ... has announced the addition of the  ...
(Date:11/26/2015)... , November 26, 2015 ... of the "Radioimmunoassay Market by Type ... Pharmaceutical Industry, Academics, Clinical Diagnostic Labs), Application ... Forecast to 2020" report to their ... announced the addition of the "Radioimmunoassay ...
(Date:11/25/2015)...  Amgen (NASDAQ: AMGN ) today announced the ... the United States (U.S.) Food and ... to Humira ® (adalimumab). Amgen believes this submission ... FDA and represents Amgen,s first BLA submission using the ... M.D., executive vice president of Research and Development at ...
Breaking Medicine Technology: